Wehealth by Servier hosted ‘AI and Big Data for Better Cancer Treatment’ forum, inviting top level experts in China’s e-health industry.
Shanghai, 22 March 2018 – WeHealth by Servier Hours hosted its first event in China — gathering a panel of experts — Chief Health Officer of IBM China, AIMIS Industry Collaboration Director from Internet Tech giant Tencent (one of the three biggest Internet conglomerate in China, generating 230 billion RMB in 2017), and Marketing VP from a leading cancer related AI start-up in China welcoming a C round financing, 12sigma, to dissect current e-health market insights and forecast future perspective together with a professional audience of 100+ distinguished audience from Bayer, Philips, Roche, Johnson Johnson, Eli lilly, Sanofi, Changsha Government, McKinsey and many others.
Sebastien Legarand, CFO of Servier China spoke for WeHealth by Servier. Mr. Sebastien introduced Servier group as well as current market situation and challenges medical start-ups may confronted with in China, depicting Servier as a friend and cooperator for e-health start-ups to develop globally with strategic plans and trustworthy resources. Through sharing Servier’s first hand industry experience and successful co-developing stories with start-up, the audience was deeply impressed by Servier’s international presence and development strategies.
WU Gang from 12sigma
“Hospitals and doctors are redefining each other.”
12 SIGMA Technologies was founded by two former Qualcomm employees with deep learning and computer vision background in April 2015 in San Diego,California. 12SIGMA is one of the first companies to introduce artificial intelligent and deep learning into modern medical image diagnosis and medical data analysis. Their headquarter is in San Diego and also have R&D teams in Beijing and Suzhou. 12SIGMA have already signed collaboration agreement with top-tier hospitals in Beijing,Shanghai and other cities in China. 12SIGMA works closely with their partners in applied medical diagnostics,technical research and clinical trials.
BAI Jing Gen from Tencent AIMIS
“It is highly possible that one day curing cancer would be as easy as curing cold in the future.”
Tencent AIMIS includes six artificial intelligence systems covering different diseases, including esophageal cancer, lung cancer, diabetic retinopathy, cervical cancer and breast cancer. Of these systems, Tencent’s early-stage esophageal cancer screening system has already entered the pre-clinical testing stage and has a reported accuracy rate of 90%. The system has been undergoing trials in Shenzhen’s Nanshan District People’s Hospital for over one month and provides screening services for dozens of patients every day.
Chen Tong from IBM China
“Medical start-ups should develop as per their strength and uniqueness.”
IBM Watson Oncology is a cognitive computing system designed to support the broader oncology community of physicians as they consider treatment options with their patients. Memorial Sloan
Kettering clinicians and analysts are partnering with IBM to train Watson Oncology to interpret cancer patients’ clinical information and identify individualized, evidence-based treatment options that leverage our specialists’ decades of experience and research.
Questions were asked for professional interpretation including
1. The challenge and limitation of AI
2. The nature of AI technologies and exaggeration
3. Opportunities and strategies for startups
4. Regulations and solutions
5. Future perspectives
After the Q&A, all speakers and audience enjoyed networking hours.
China’s medical AI industry is facing fast moving dynamics as the government has not established standards for data access and technology restriction. This not only provides full possibilities for all insiders but also generates headaches for start-ups as the potential is unprecedented. However, AI is welcomed as a solution to tackle with doctor shortages by the government, so policy is still supportive for the market.
The main challenge for China’s medical AI development is the access to quality EMR. How to convince hospitals and institutes to undertake the potential risks is still a big question mark.